UBS analyst Kevin Caliendo maintains $Owens & Minor (OMI.US)$ with a buy rating, and adjusts the target price from $28 to $25.
According to TipRanks data, the analyst has a success rate of 54.7% and a total average return of 4.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Owens & Minor (OMI.US)$'s main analysts recently are as follows:
Owens & Minor's Q3 results presented a combination of expectations and variability, with revenues aligning with projections but segment profitability showing inconsistency. The company is actively addressing its eligibility backlog, which stems from the Change hack incident.
The company's third-quarter performance, which surpassed expectations, was counterbalanced by a reduction in the profitability outlook for fiscal year 2024 alongside concerns regarding negative free cash flow.
The company experienced a mixed quarter, with notable EBIT growth in the Patient Direct segment contrasting with weaker performance in Product & Health Services. The standout for the quarter was the robust operating margin observed in Patient Direct. However, there is a growing concern regarding margin pressure in medical distribution, which raises further questions about competitive movements within the industry and brings about a more cautious stance on the outlook for margin progression leading into 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞士银行分析师Kevin Caliendo维持$欧麦斯-麦能医疗 (OMI.US)$买入评级，并将目标价从28美元下调至25美元。
根据TipRanks数据显示，该分析师近一年总胜率为54.7%，总平均回报率为4.4%。
此外，综合报道，$欧麦斯-麦能医疗 (OMI.US)$近期主要分析师观点如下：
Owens ＆ Minor的第三季度业绩呈现出预期和变化各异的组合，营收与预期一致，但分部利润率表现不稳定。公司正在积极处理其由Change黑客事件引起的资格积压问题。
公司第三季度表现超过预期，但与此同时，2024财年利润前景下调，同时出现负自由现金流的担忧。
公司经历了一个波澜起伏的季度，患者直销板块的显着EBIt增长形成鲜明对比，而产品与健康服务板块的表现较弱。该季度的亮点是患者直销板块观察到的强劲营业利润率。然而，医疗分配方面的利润率压力引起了日益关注，这引发了有关行业内竞争动态的进一步问题，并对2025年利润率进展前景持更为谨慎的立场。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
